Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous dosing study of DYD-301 tablet in Japanese patients with Lambert Eaton Myasthenic Syndrome (Expanded Access Program)
jRCT2031220702Active, not recruiting
- Sponsor
- DyDo Pharma,Inc.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amifampridine in Lambert-Eaton myasthenic syndrome (LEMS), sponsored by DyDo Pharma,Inc. Primary endpoints: Adverse events and adverse drug reactions, Vital signs and 2 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
amifampridine
03
Conditions
Lambert-Eaton myasthenic syndrome (LEMS)
Beyond the preview
Go deeper on jRCT2031220702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220702.